Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.
about
Neurodevelopmental benefits of antiretroviral therapy in Ugandan children aged 0-6 years with HIV.HIV Prevention and Intervention in Psychiatrically Ill Youths.Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy.Youths and HIV/AIDS: psychiatry's role in a changing epidemicLanguage impairment in children perinatally infected with HIV compared to children who were HIV-exposed and uninfected.Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children.Neurodevelopmental trajectory of HIV-infected children accessing care in Kinshasa, Democratic Republic of Congo.Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.Lower total and regional grey matter brain volumes in youth with perinatally-acquired HIV infection: Associations with HIV disease severity, substance use, and cognition.Feasibility assessment of cerebrospinal fluid from HIV-1-infected children for HIV proviral DNA and monocyte chemoattractant protein 1 alleles.Design of the silent cerebral infarct transfusion (SIT) trial.The neurodevelopment of HIV-infected infants on HAART compared to HIV-exposed but uninfected infants.Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART).
P2860
Q34342177-FBE6CC3C-402A-4B72-9860-FCE6B91644E9Q34424453-C5278583-4F1B-46B1-9706-86CEC7E8DA00Q34731516-06F1734B-8001-4B8C-AD2B-074CE8C8D446Q35126792-8C556DD0-D936-4EA5-978B-E6A4D78DDF28Q35848277-CAEE4B13-C98C-4662-BB92-F234AB113D7BQ35959808-C477DB78-5C81-4325-B3F5-EF97554AD9DBQ37456754-50827906-1B33-4F21-BAD7-8068760ABFD5Q38210096-DAB04618-A6D4-40F5-8003-7AF30D573FA4Q38770217-F1259DA3-1E46-41AB-BFD4-EE25C6AD5B62Q40260121-4CD07365-E2D5-4506-B14A-B70F31BD3D14Q41527748-FB001EA6-9D13-431E-A5E9-8CA0EDA17BCBQ42244270-4A08E9F5-FFF7-4228-AB1E-FE569C668F7FQ48415542-FDA85078-770D-447F-86A6-E607138746CF
P2860
Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Neurologic, neurocognitive, an ...... l Trials Group 152 Study Team.
@en
Neurologic, neurocognitive, an ...... l Trials Group 152 Study Team.
@nl
type
label
Neurologic, neurocognitive, an ...... l Trials Group 152 Study Team.
@en
Neurologic, neurocognitive, an ...... l Trials Group 152 Study Team.
@nl
prefLabel
Neurologic, neurocognitive, an ...... l Trials Group 152 Study Team.
@en
Neurologic, neurocognitive, an ...... l Trials Group 152 Study Team.
@nl
P2093
P356
P1433
P1476
Neurologic, neurocognitive, an ...... l Trials Group 152 Study Team.
@en
P2093
Brouwers P
Englund JA
Lifschitz MH
McKinney RE
O'Donnell K
Pearson DA
P356
10.1542/PEDS.104.3.E32
P407
P577
1999-09-01T00:00:00Z